Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice

(2010) Daniel J. DeAngelo et al.   LEUKEMIA & LYMPHOMA

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

(2010) Kazuhito Naka et al.   NATURE

Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

(2009) Massimo Breccia et al.   CURRENT DRUG TARGETS

The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells

(2009) F Belloc et al.   LEUKEMIA

Oxidative Stress in the Regulation of Normal and Neoplastic Hematopoiesis

(2008) Saghi Ghaffari   ANTIOXIDANTS & REDOX SIGNALING

Regulation of Reactive Oxygen Species and Genomic Stability in Hematopoietic Stem Cells

(2008) Kazuhito Naka et al.   ANTIOXIDANTS & REDOX SIGNALING

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors

(2008) H Konig et al.   LEUKEMIA

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases

(2008) Artur Gontarewicz et al.   LEUKEMIA RESEARCH